Annals of internal medicine
-
Randomized Controlled Trial
Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to alter the natural history of chronic kidney disease (CKD), and they should be included in cost-effectiveness analyses of screening for CKD. ⋯ Agency for Healthcare Research and Quality, Veterans Affairs Office of Academic Affiliations, and National Institute of Diabetes and Digestive and Kidney Diseases.
-
Comment Randomized Controlled Trial Multicenter Study
Genotype-guided drug prescribing vs. usual care reduced clinically relevant adverse drug reactions at 12 wk.
Swen JJ, van der Wouden CH, Manson LE, et al; Ubiquitous Pharmacogenetics Consortium. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347-356. 36739136.
-
Comment Randomized Controlled Trial
In hypertension not treated with medications, renal denervation vs. sham reduced daytime ambulatory SBP at 2 mo.
Azizi M, Saxena M, Wang Y, et al; RADIANCE II Investigators and Collaborators. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023;329:651-661. 36853250.
-
Randomized Controlled Trial
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. ⋯ Latona Foundation, FastGrants, and Rainwater Charitable Foundation.
-
Randomized Controlled Trial
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life. ⋯ National Institute of Allergy and Infectious Diseases of the National Institutes of Health.